Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial

Table 7 Subgroup results of fundus photography hemorrhage evaluation, mean ± SD

Fundus photography hemorrhage evaluation	Subgroup	n (CDDP/placebo)	CDDP changes from 24 weeks to baseline	Placebo changes from 24 weeks to baseline	Within-group comparison statistic (Wilcoxon rank-sum test)	95%CI	P value
NPDR severity	Mild	127/48	0.01 ± 0.09	0.13 ± 0.46	2.673	-0.21 to -0.04	0.007
	Moderate	182/56	-0.40 ± 1.34	0.57 ± 2.20	3.581	-1.46 to -0.49	< 0.001
	Severe	53/17	-0.63 ± 1.46	0.43 ± 1.83	0.211	-2.05 to -0.06	0.004
HbA1c	< 7%	197/64	-0.27 ± 1.04	-0.05 ± 1.28	1.448	-0.54 to 0.10	0.147
	≥ 7%	163/55	-0.31 ± 1.20	0.88 ± 1.97	5.717	-1.65 to -0.73	< 0.001
Duration of diabetes	< 5 years	57/23	-0.51 ± 1.36	-0.14 ± 1.42	2.106	-1.07 to 0.32	0.035
	≥ 5 years	305/98	-0.23 ± 1.05	0.51 ± 1.72	4.884	-1.04 to -0.44	< 0.001

NPDR: Non-proliferative diabetic retinopathy; CDDP: Compound danshen dripping pill.